drugset / Trial / NCT02057302

A Study on Postmarketing Xuezhikang Capsule for Treating Dyslipidemia

NCT02057302

Phase 4 Completed 2400 enrolled China Academy of Chinese Medical Sciences
RandomizedParallel-groupDouble-blindTreatment

Summary

Dyslipidemia contributes greatly to the formation and progression of atherosclerosis (AS), which plays a dominant role in leading to CHD. Xuezhikang is a partially purified extract of fermented red yeast rice (Monascus purpureus). It is composed of 13 kinds of natural statins, unsaturated fatty acids, ergosterol,amino acids, flavonoids, alkaloid, trace element, and so forth. Xuezhikang has been recommended in a guideline for China adult dyslipidemia prevention. This study aims to evaluate the benefit and side effect of Xuezhikang, a potential alternative drug of statins, for patients with dyslipidemia, and thus provide further evidence for clinical application.

Timeline

Start
2010-03
Primary completion
2012-12
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Xuezhikang Traditional medicine (herbal / TCM) 2 unknown Oral

Indications